Patents by Inventor Tamie Jo Chilcote

Tamie Jo Chilcote has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Prodrugs of inhibitors of plasma kallikrein
    Patent number: 9206123
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Grant
    Filed: November 8, 2013
    Date of Patent: December 8, 2015
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20140128436
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Application
    Filed: November 8, 2013
    Publication date: May 8, 2014
    Applicant: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • Prodrugs of inhibitors of plasma kallikrein
    Patent number: 8691861
    Abstract: This invention provides new pharmaceutically useful compounds that are prodrugs of inhibitors of plasma kallikrein and methods and compositions for preventing or treating plasma kallikrein dependent diseases or conditions, such as diabetic macular edema or hemorrhagic stroke, by administering prodrugs of the formula:
    Type: Grant
    Filed: April 12, 2012
    Date of Patent: April 8, 2014
    Assignee: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote, Joghee Raju Suresh, Sriram Narasimhan
  • Methods for treatment of kallikrein-related disorders
    Patent number: 8658685
    Abstract: We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: February 25, 2014
    Assignees: Activesite Pharmaceuticals, Inc., Joslin Diabetes Center
    Inventors: Lloyd P. Aiello, Tamie Jo Chilcote, Sukanto Sinha, Edward P. Feener
  • Prodrugs of inhibitors of plasma kallikrein
    Patent number: 8609866
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: December 17, 2013
    Assignee: ActiveSite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • PRODRUGS OF INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20120264798
    Abstract: This invention provides new pharmaceutically useful compounds that are prodrugs of inhibitors of plasma kallikrein and methods and compositions for preventing or treating plasma kallikrein dependent diseases or conditions, such as diabetic macular edema or hemorrhagic stroke, by administering prodrugs of the formula:
    Type: Application
    Filed: April 12, 2012
    Publication date: October 18, 2012
    Applicant: Activesite Pharmaceuticals, Inc.
    Inventors: Sukanto SINHA, Tamie Jo Chilcote, Joghee Raju Suresh, Sriram Narasimhan
  • Inhibitors of plasma kallikrein
    Patent number: 8258170
    Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
    Type: Grant
    Filed: June 6, 2011
    Date of Patent: September 4, 2012
    Assignee: Activesite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20110301215
    Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
    Type: Application
    Filed: June 6, 2011
    Publication date: December 8, 2011
    Applicant: Activesite Phamaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • Inhibitors of plasma kallikrein
    Patent number: 7977380
    Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: July 12, 2011
    Assignee: Activesite Pharmaceticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • PRODRUGS OF INHIBITORS OF PLASMA KALLIKRIEN
    Publication number: 20110152533
    Abstract: The present invention provides prodrugs of compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating plasma kallikrein dependent diseases or conditions, for example, diabetic macular edema, with the prodrugs having the formula:
    Type: Application
    Filed: December 17, 2010
    Publication date: June 23, 2011
    Applicant: Activesite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • METHODS FOR TREATMENT OF KALLIKREIN-RELATED DISORDERS
    Publication number: 20110065757
    Abstract: We have identified classes of kallikrein inhibitors as compounds that are useful in the reduction of vascular permeability (e.g., retinal vascular permeability and cerebral vascular permeability) and astrocyte activation. Diseases and conditions associated with increased vascular permeability include diabetic retinopathy, hemorrhagic stroke, and macular edema. Diseases and conditions associated with astrocyte activation include Alzheimer's disease, multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis, Creutzfeldt-Jakob disease, stroke, epilepsy, and brain trauma.
    Type: Application
    Filed: January 30, 2009
    Publication date: March 17, 2011
    Applicants: JOSKIN DIABETES CENTER, ACTIVESITE PHARMACEUTICALS, INC.
    Inventors: Lloyd P. Aiello, Tamie Jo Chilcote, Sukanto Sinha, Edward P. Feener
  • INHIBITORS OF PLASMA KALLIKREIN
    Publication number: 20100130563
    Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
    Type: Application
    Filed: November 20, 2009
    Publication date: May 27, 2010
    Applicant: Activesite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • Inhibitors of plasma kallikrein
    Patent number: 7625944
    Abstract: The present invention provides compounds that inhibit the activity of plasma kallikrein (PK) and methods of preventing and treating the formation of thrombin during or after a PK dependent disease or condition, for example, after fibrinolysis treatment.
    Type: Grant
    Filed: July 30, 2007
    Date of Patent: December 1, 2009
    Assignee: Activesite Pharmaceuticals, Inc.
    Inventors: Sukanto Sinha, Tamie Jo Chilcote
  • METHODS FOR IDENTIFICATION OF INHIBITORS OF ENZYME ACTIVITY
    Publication number: 20090215080
    Abstract: The invention discloses compositions and methods of synthesis to create novel ligands and drugs and identifying such compounds as inhibitors of enzyme targets for use in the treatment of clinical disorders, including cancer, infectious diseases, parasitic infestations, neurological disorders, reproductive disorders, inflammatory disorders, circulatory disorders, and metabolic disorders.
    Type: Application
    Filed: October 12, 2006
    Publication date: August 27, 2009
    Applicant: ActiveSite Pharmaceuticals
    Inventors: Sukanto Sinha, Tamie Jo Chilcote